 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 05/07/2008 | | | | Nymox Reports New Large Cohort U.S. 3 Year Follow-Up Clinical Study of NX-1207 for BPH Near Completion
topic: R&D: BPH (enlarged prostate) Treatments
May 7, 2008: Nymox announced today that a large new 3 year follow-up study of NX-1207 for benign prostatic hyperplasia is near completion. The study evaluated symptomatic progress of over one hundred subjects involved in the Company’s Phase 2 U.S. clinical trial initiated in 2005. Individuals in the study were assessed 3 years after NX-1207 treatment for symptomatic improvement, treatment outcomes, and durability of efficacy. The Company anticipates the reporting of final results and statistical analysis for the study within the next 2-3 weeks. |
| 05/06/2008 | | | | Brief Exposure to Second-Hand Smoke Bad for Health According to New Study
topic: Tobacco Exposure Tests
May 6, 2008: Nymox offers TobacAlert™ Urine, an easy-to-use test for second-hand smoke exposure that requires no special equipment or training and can be used for at home or at the workplace. Even a brief exposure to second-hand smoke may hurt human blood vessels according to a new study published in the most recent issue of the Journal of the American College of Cardiology. |
| 04/30/2008 | | | | Nymox Announces New Positive Results at 54 Months in Long Term Study of NX-1207 for Benign Prostatic Hyperplasia
topic: R&D: BPH (enlarged prostate) Treatments
April 30, 2008: Nymox today announced new positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company’s two Phase 1-2 studies initiated in 2003. Overall, 75% of the patients in the new outcome study treated with NX-1207 reported no current drug treatment for their BPH and had a mean improvement of 11.1 points in AUA Symptom Score. In addition, 38% of the patients reported no other approved treatments at any time for their BPH since their original treatment with NX-1207, with a mean improvement of 9.8 points. |
| 04/22/2008 | | | | New Peer Review Publications Support Nymox Saliva Smoking Test
topic: Tobacco Exposure Tests
April 22, 2008: Nymox announced today the publication of new independent studies finding that the Company's NicAlert™ Saliva product provides an accurate, convenient and cost-effective way to verify self-reported smoking status with broad potential applications both in the clinic and in large research trials and surveys. |
| 04/17/2008 | | | | Nymox Announces Clinical Study Presentation on BPH Drug at American Urological Association Meeting
topic: R&D: BPH (enlarged prostate) Treatments
April 17, 2008: Nymox announced that new clinical trial data concerning the safety and efficacy of the Company’s NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the South Central Section of the American Urological Association Meeting in San Diego in September. |
| 04/15/2008 | | | | Nymox Nears Completion of Latest U.S. Study of NX-1207 for Benign Prostatic Hyperplasia
topic: R&D: BPH (enlarged prostate) Treatments
April 15, 2008: Nymox announced today that the Company’s latest multi-center U.S. Phase 2 study of its proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia (BPH) is nearing completion. The Company anticipates the reporting of final results and statistical analysis for the study within the next few weeks. |
| 04/01/2008 | | | | Nymox Releases Positive New Clinical Trial Data on Response Rates to Company’s Prostate Drug NX-1207
topic: R&D: BPH (enlarged prostate) Treatments
April 1, 2008: Nymox announced today the release of positive new clinical trial data from the Company’s latest multi-center U.S. Phase 2 study of NX-1207, Nymox’s innovative drug treatment for benign prostatic hyperplasia (BPH). In the study’s Intent-to-Treat group at 3 months, more than four times as many positive responses to treatment were documented in subjects randomized to the NX-1207 therapeutic dose as compared to subjects randomized to the comparator finasteride, an approved drug for BPH. |
| 03/14/2008 | | | | Nymox Reports 2007 Financial Results
topic: Financial
March 14, 2008: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the year ended December 31, 2007. |
| 03/11/2008 | | | | Nymox Releases Further Results from Latest U.S. Study of NX-1207 for Benign Prostatic Hyperplasia
topic: R&D: BPH (enlarged prostate) Treatments
March 11, 2008: Nymox announced today that results from the Company’s new multi-center U.S. Phase 2 study showed evidence that the Company’s proprietary drug NX-1207 can markedly reduce the incidence of nighttime urination (nocturia), a particularly bothersome symptom associated with benign prostatic hyperplasia (BPH). After 90 days, subjects treated with a therapeutic dose of NX-1207 had a statistically significant mean % reduction in nocturia symptom score of 41% versus 4% for subjects treated with finasteride, an approved BPH treatment. |
| 02/20/2008 | | | | Nymox’s NX-1207 Offers a New and Attractive Approach to the Treatment of Benign Prostatic Hyperplasia
topic: R&D: BPH (enlarged prostate) Treatments
February 20, 2008: Nymox provided an outline today of the outstanding potential the Company’s proprietary drug, NX-1207, has for the treatment of the common condition of enlarged prostate or benign prostatic hyperplasia (BPH). In clinical trials, NX-1207 treatment for BPH has shown a superior safety and efficacy profile compared to those reported for current FDA approved BPH treatments. In two multi-center Phase 2 U.S. prospective randomized blinded clinical trials, the aggregated mean improvement in BPH Symptom Score for 2.5 mg NX-1207 was 10.3 points (n=85) 3 months after a single treatment. Follow-up studies have shown evidence of a durable benefit of 2 years or more for many patients. |
|